11
Proprietary Decision Instruments
SAR 3.5B+
Annual preventable claims losses in Saudi healthcare
SAR 40–65B
VBHC savings potential by 2035 (PwC)
5.88%
Current AI adoption rate in Saudi hospitals

Decision Assurance for High-Stakes Healthcare

We are not a consulting firm, an analytics vendor, or an AI company. HealthElevate operates above vendors and below boards — providing independent analytical judgment through proprietary Decision Instruments when it matters most.

Decision Instruments

Eleven proprietary instruments across VBHC readiness, AI governance, population health, revenue sustainability, and regulatory preparedness — each delivering a clear Proceed, Delay, or Redesign recommendation.

Independent Analysis

Every engagement is grounded exclusively in publicly available data and information provided by the client organisation. Vendor-neutral, COI-protected, and designed to withstand board-level scrutiny. Our independence is the value.

Board-Ready Outputs

Every engagement concludes with a structured written brief: section-by-section risk analysis, an explicit Proceed / Delay / Redesign recommendation, and a summary ready for executive or board presentation.

Published Independence Commitments

Our conflict-of-interest framework defines with precision what we do and what we do not do. These are binding operational constraints, not marketing language.

What We Provide

  • Independent analytical and diagnostic services
  • Decision Instruments applied to client-specific contexts
  • Analytical articles from publicly available data only
  • Board-ready written briefs with structured recommendations
  • Proceed, Delay, or Redesign recommendations with conditions

What We Do Not Provide

  • Vendor go-to-market support or market entry assistance
  • Regulatory navigation services
  • Stakeholder introductions
  • Implementation services of any kind
  • Ongoing retainer or operational advisory
  • Analysis drawing on non-public data sources

Instrument-Led. Evidence-Backed.

Every HealthElevate engagement follows the same four-stage diagnostic process. This consistency allows outputs to be compared across engagements and built into board reporting cycles.

1
Decision Scoping
Identify the precise decision being made and its irreversibility threshold. Define what a bad outcome looks like. Clarify who carries accountability.
2
Instrument Application
Apply the relevant Decision Instrument across defined dimensions. Responses rated Strong, Partial, or Weak against evidence criteria.
3
Risk Profile Construction
Aggregate responses into a structured risk profile. Surface failure modes, gaps, and exposure concentrations within the organisation's control.
4
Recommendation Delivery
Issue a clear Proceed, Delay, or Redesign recommendation with conditions, supported by a board-ready written brief with section-by-section risk analysis.

Founded to Fill a Specific Gap

HealthElevate Ltd is incorporated in England and Wales (Company No. 16913517) and registered in London. The organisation was established to address a specific and persistent gap in the Saudi Arabia and GCC healthcare market: the absence of structured, independent, decision-focused analytical support for executives facing consequential choices.

The founding expertise draws on deep operational knowledge of Saudi Arabia's healthcare financing system — including claims management, NPHIES operations, population health management, and value-based contracting — combined with the professional independence required to deliver objective diagnostic work without the conflicts that characterise vendor-aligned advisory.

HealthElevate exists to serve one function: ensuring that the decisions shaping healthcare systems are made with the rigour they deserve. Not after the contract is signed. Before.

All analytical work is conducted from publicly available data sources only, in strict accordance with our published conflict-of-interest framework. Our scope deliberately excludes implementation, vendor support, and regulatory navigation.

11
Proprietary Decision Instruments across the healthcare decision lifecycle
SAR 3.5B+
Annual preventable claims losses in Saudi healthcare (industry estimate)
SAR 40–65B
PwC estimate of annual VBHC savings potential in Saudi Arabia by 2035
5.88%
Current AI adoption rate in Saudi hospitals — significant structural opportunity

Ready to bring rigour to your next critical decision?

Every engagement begins with a focused conversation about your specific decision context. No open-ended retainers. No jargon. Structured analytical support, precisely scoped.

How to Engage View Instruments